Written by the Sakura Skin team. Medically reviewed by Bethany S. Campbell, JD, RN, Sakura Skin Medical Spa, Fenton & Flint, MI. Published October 25, 2026. Last updated October 25, 2026.
Short answer: A 2026 study in mice found that tirzepatide (the medication in Mounjaro and Zepbound) activated brown fat, the kind of fat that burns energy as heat, and improved glucose tolerance beyond what eating less alone explained. But treated mice didn’t lose more weight than mice simply eating the same amount, and the research hasn’t been confirmed in people. It’s a promising clue, not a reason to change your dose or treatment plan.
Do GLP-1 medications do more than turn down your appetite? New research suggests tirzepatide, the medication in Mounjaro and Zepbound, may also influence how your body uses energy. The findings are early, but they add to a growing picture of how these medications work.
Not All Body Fat Is the Same
Your body has more than one kind of fat:
- White fat stores excess energy
- Brown fat is packed with mitochondria that convert energy into heat, a process called thermogenesis
Unlike white fat, which primarily stores energy, brown fat can actively expend it. That’s why researchers have long been interested in whether activating brown fat could support metabolic health and weight management.
What Did the New Study Find?
Researchers at the University of Barcelona studied how tirzepatide affects brown fat and metabolism. Their work was published in Biomedicine & Pharmacotherapy in 2026.
The study used mice with diet-induced obesity. To separate the drug’s effects from simply eating less, researchers compared mice given tirzepatide with mice fed the same reduced amount of food without the drug. They found:
- Brown fat was activated, and energy-related metabolic signaling changed
- Batokines, signaling molecules released by brown fat, changed
- Glucose tolerance improved independently of reduced food intake
Does This Mean Tirzepatide Actually Burns More Calories?
Possibly, but not necessarily. Activating brown fat doesn’t automatically mean meaningful extra calorie burn.
In fact, the drug-treated mice and the calorie-matched mice lost similar amounts of weight. These findings are not proof that tirzepatide raises metabolism in people. More research is needed to understand how this applies to humans and to long-term weight management.
Why This Research Matters for Weight Loss
“Eat less and move more” oversimplifies a complicated problem. Many factors contribute to obesity, including:
- Appetite
- Hormones
- Insulin sensitivity
- Genetics
- Metabolic adaptation
- Energy expenditure
Tirzepatide acts on two receptors:
- GLP-1 receptors, which affect appetite, fullness, and blood sugar regulation
- GIP receptors, which affect insulin secretion and metabolic regulation
That combination helps explain tirzepatide’s weight-loss results in clinical trials. For a deeper look, see What Is Tirzepatide? Zepbound and Mounjaro Explained.
What About Muscle Loss During Weight Loss?
This study didn’t focus on muscle, but preserving lean muscle is important. When you lose weight, you can lose both fat and lean tissue. You can help protect your muscle with:
- Adequate protein
- Resistance training
- Appropriate nutrition
- Medical monitoring
The goal is to lose excess body fat while maintaining your strength, function, and metabolic health. Our post on keeping weight off after GLP-1 medication covers this in more detail.
What Does This Mean for You If You’re Taking a GLP-1 Medication?
There’s good reason for optimism about obesity treatment, but keep these points in mind:
- This research was done in animals
- It doesn’t show that tirzepatide raises resting metabolic rate or causes extra weight loss through brown fat in people
- It doesn’t justify increasing your dose or changing your treatment
- Successful weight management requires an individualized approach
The Bottom Line: Weight Loss Is About More Than Willpower
Your body weight is shaped by hormones, appetite, metabolism, and energy expenditure. Human research is still needed, but this study is another reminder that obesity is a complex medical condition, and effective treatment involves more than simply telling someone to eat less.
At Sakura Skin, we believe medical weight management should improve your overall health, preserve your muscle, and support a sustainable long-term plan.
Interested in Medical Weight Management?
We offer individualized consultations, including GLP-1-based therapies when clinically indicated. Our approach includes a medical evaluation, patient education, realistic goals, and ongoing support.
Sakura Skin has locations at 13389 Pomona Drive in Fenton, MI and 2335 S. Linden Road, Suite B in Flint, MI, serving Fenton, Flint, Linden, Holly, Grand Blanc, Swartz Creek, Davison, and Hartland.
Want to learn more about our medical weight-management services? Call 810-394-2187 or Text 810-512-2496 — or book online at calendly.com/sakuraskin. We’re in Fenton and Flint, MI.
Scientific References
- Mestres-Arenas A, et al. Differential effects of the anti-obesity drug tirzepatide on adipose tissues: Brown fat as a key target. Biomedicine & Pharmacotherapy. 2026;195:119057. https://doi.org/10.1016/j.biopha.2026.119057
- ScienceDaily. Zepbound and Mounjaro may turn on the body’s calorie-burning brown fat. September 2026. https://www.sciencedaily.com/releases/2026/09/260925093210.htm
Individual results vary. This article is for educational purposes only and is not individualized medical advice. The brown-fat findings come from animal research and have not been shown to be clinically meaningful in humans. Prescription weight-loss medications carry risks, side effects, and contraindications and should be used only under qualified medical supervision. Talk with your healthcare provider before starting, changing, or stopping any medication or weight-loss program.